Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models
<b>Background/Objectives:</b> Aromatase plays a crucial role in the conversion of androgens to oestrogens and is often overexpressed in hormone-dependent tumours, particularly breast cancer. [18F]BIBD-071, which has excellent binding affinity for aromatase and good pharmacokinetics, has...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/66 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587711564742656 |
|---|---|
| author | Di Fan Xin Wang Xueyuan Ling Hongbin Li Lu Zhang Wei Zheng Zehui Wu Lin Ai |
| author_facet | Di Fan Xin Wang Xueyuan Ling Hongbin Li Lu Zhang Wei Zheng Zehui Wu Lin Ai |
| author_sort | Di Fan |
| collection | DOAJ |
| description | <b>Background/Objectives:</b> Aromatase plays a crucial role in the conversion of androgens to oestrogens and is often overexpressed in hormone-dependent tumours, particularly breast cancer. [18F]BIBD-071, which has excellent binding affinity for aromatase and good pharmacokinetics, has potential for the diagnosis and treatment of aromatase-related diseases. The MCF-7 cell line, which is hormone receptor-positive (HR+), was used in the assessment of the novel [18F]-labelled radiotracer [18F]BIBD-071 via positron emission tomography (PET) imaging of an HR+ breast cancer xenograft model. <b>Methods:</b> [18F]BIBD-071 was synthesised, radiolabelled, and then subjected to in vitro stability testing. MCF-7 cells were cultured and implanted into BALB/c nude mice to establish subcutaneous tumour models. MicroPET/CT imaging was conducted after injection of the tracer at 1 and 2 h, and a blocking study was also conducted using the aromatase inhibitor letrozole. A block experiment was used to prove the specificity of the probe. Biodistribution studies were performed at 0.5, 1, and 2 h post injection (p.i.). Immunofluorescence was used to assess aromatase expression in MCF-7 cells. <b>Results:</b> [18F]BIBD-071 showed excellent in vitro stability and specific uptake in an MCF-7 xenograft tumour model. MicroPET/CT imaging at 1 and 2 h p.i. revealed excellent tumour visualisation with a favourable tumour-to-background ratio. Biodistribution data revealed high tracer uptake in the liver, small intestine, and stomach, with significant washout from the bloodstream and tumour over time. The tumour uptakes at 0.5 h, 1 h, and 2 h were 3.84 ± 0.13, 2.5 ± 0.17, and 2.54 ± 0.32, respectively. The tumour uptake significantly decreased between 0.5 h and 1 h (<i>p</i> < 0.0001), whereas there was no significant difference between 1 and 2 h. The tumour/background ratios at 0.5 h, 1 h, and 2 h were 1.19 ± 0.03, 1.12 ± 0.17, and 1.42 ± 0.11, respectively. Immunofluorescence confirmed robust aromatase expression in MCF-7 cells, which was correlated with [18F]BIBD-071 tumour uptake. <b>Conclusions:</b> [18F]BIBD-071 is a promising PET tracer for diagnosing and monitoring HR+ breast cancer, warranting further research into hormone-dependent cancers. |
| format | Article |
| id | doaj-art-6376a8c82b224260b3bec80c08aafca0 |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-6376a8c82b224260b3bec80c08aafca02025-01-24T13:45:15ZengMDPI AGPharmaceuticals1424-82472025-01-011816610.3390/ph18010066Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse ModelsDi Fan0Xin Wang1Xueyuan Ling2Hongbin Li3Lu Zhang4Wei Zheng5Zehui Wu6Lin Ai7Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, ChinaDepartment of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, ChinaDepartment of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, ChinaBeijing Institute of Brain Disorders, Capital Medical University, Beijing 100069, ChinaBeijing Institute of Brain Disorders, Capital Medical University, Beijing 100069, ChinaBeijing Institute of Brain Disorders, Capital Medical University, Beijing 100069, ChinaDepartment of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, China<b>Background/Objectives:</b> Aromatase plays a crucial role in the conversion of androgens to oestrogens and is often overexpressed in hormone-dependent tumours, particularly breast cancer. [18F]BIBD-071, which has excellent binding affinity for aromatase and good pharmacokinetics, has potential for the diagnosis and treatment of aromatase-related diseases. The MCF-7 cell line, which is hormone receptor-positive (HR+), was used in the assessment of the novel [18F]-labelled radiotracer [18F]BIBD-071 via positron emission tomography (PET) imaging of an HR+ breast cancer xenograft model. <b>Methods:</b> [18F]BIBD-071 was synthesised, radiolabelled, and then subjected to in vitro stability testing. MCF-7 cells were cultured and implanted into BALB/c nude mice to establish subcutaneous tumour models. MicroPET/CT imaging was conducted after injection of the tracer at 1 and 2 h, and a blocking study was also conducted using the aromatase inhibitor letrozole. A block experiment was used to prove the specificity of the probe. Biodistribution studies were performed at 0.5, 1, and 2 h post injection (p.i.). Immunofluorescence was used to assess aromatase expression in MCF-7 cells. <b>Results:</b> [18F]BIBD-071 showed excellent in vitro stability and specific uptake in an MCF-7 xenograft tumour model. MicroPET/CT imaging at 1 and 2 h p.i. revealed excellent tumour visualisation with a favourable tumour-to-background ratio. Biodistribution data revealed high tracer uptake in the liver, small intestine, and stomach, with significant washout from the bloodstream and tumour over time. The tumour uptakes at 0.5 h, 1 h, and 2 h were 3.84 ± 0.13, 2.5 ± 0.17, and 2.54 ± 0.32, respectively. The tumour uptake significantly decreased between 0.5 h and 1 h (<i>p</i> < 0.0001), whereas there was no significant difference between 1 and 2 h. The tumour/background ratios at 0.5 h, 1 h, and 2 h were 1.19 ± 0.03, 1.12 ± 0.17, and 1.42 ± 0.11, respectively. Immunofluorescence confirmed robust aromatase expression in MCF-7 cells, which was correlated with [18F]BIBD-071 tumour uptake. <b>Conclusions:</b> [18F]BIBD-071 is a promising PET tracer for diagnosing and monitoring HR+ breast cancer, warranting further research into hormone-dependent cancers.https://www.mdpi.com/1424-8247/18/1/66[18F]BIBD-071HR+ breast canceraromatasePET/CT |
| spellingShingle | Di Fan Xin Wang Xueyuan Ling Hongbin Li Lu Zhang Wei Zheng Zehui Wu Lin Ai Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models Pharmaceuticals [18F]BIBD-071 HR+ breast cancer aromatase PET/CT |
| title | Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models |
| title_full | Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models |
| title_fullStr | Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models |
| title_full_unstemmed | Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models |
| title_short | Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models |
| title_sort | utilisation of the innovative 18f labelled radiotracer 18f bibd 071 within hr breast cancer xenograft mouse models |
| topic | [18F]BIBD-071 HR+ breast cancer aromatase PET/CT |
| url | https://www.mdpi.com/1424-8247/18/1/66 |
| work_keys_str_mv | AT difan utilisationoftheinnovative18flabelledradiotracer18fbibd071withinhrbreastcancerxenograftmousemodels AT xinwang utilisationoftheinnovative18flabelledradiotracer18fbibd071withinhrbreastcancerxenograftmousemodels AT xueyuanling utilisationoftheinnovative18flabelledradiotracer18fbibd071withinhrbreastcancerxenograftmousemodels AT hongbinli utilisationoftheinnovative18flabelledradiotracer18fbibd071withinhrbreastcancerxenograftmousemodels AT luzhang utilisationoftheinnovative18flabelledradiotracer18fbibd071withinhrbreastcancerxenograftmousemodels AT weizheng utilisationoftheinnovative18flabelledradiotracer18fbibd071withinhrbreastcancerxenograftmousemodels AT zehuiwu utilisationoftheinnovative18flabelledradiotracer18fbibd071withinhrbreastcancerxenograftmousemodels AT linai utilisationoftheinnovative18flabelledradiotracer18fbibd071withinhrbreastcancerxenograftmousemodels |